Pharmaceutical company AbbVie announced Wednesday its plans to construct a $1.4 billion manufacturing facility in North Carolina, representing the largest investment the drugmaker has ever made at a single location.
The expansive campus will function as AbbVie’s primary United States center for producing injectable medications, distributing treatments both within the country and internationally as the company boosts its domestic manufacturing capabilities.
Located on 185 acres in Durham, North Carolina, the new facility will produce treatments for immune system conditions, cancer, and neurological disorders.
Over a four-year period, AbbVie expects to bring on 734 workers at the site, including engineers, research scientists, and manufacturing personnel.
Development of the project is scheduled to begin in 2026, with completion targeted for late 2028. The construction phase alone is projected to create more than 2,000 temporary jobs.
The initial construction phase will feature manufacturing buildings, research laboratories, warehouse space, administrative offices, and worker amenities.
This announcement follows AbbVie’s February commitment to spend $380 million on two new pharmaceutical ingredient production facilities at its North Chicago, Illinois headquarters, aimed at expanding domestic production of treatments for neurological conditions and obesity.
The North Carolina development represents part of AbbVie’s broader strategy to invest approximately $100 billion in United States research, development, and manufacturing operations over the coming decade.
Within the past year alone, the pharmaceutical company has allocated more than $2.2 billion toward manufacturing projects across the country.
